According to Alexander Prokhorov, head of the Moscow Investment and Industrial Policy Department, the new resident of the Technopolis Moscow special economic zone will make drugs for the treatment of orphan diseases. This is reported on the official website of the mayor of Moscow.
“The company has rented premises with a total area of 518 square meters at the Alabushevo site, which it plans to modernize for secondary packaging this year. At the second stage of the investment project, by 2024, the resident will build its own plant at the same location, in Zelenograd. The total volume of planned investments in the project will be almost five billion rubles; at least 250 jobs are expected to be created at the enterprise,” he said.
The resident will also produce drugs for the treatment of asthma, cardiovascular, rare and hereditary diseases. These are, for example, Gaucher’s disease and cystic fibrosis. After the company launches its own workshops, it will produce substances and finished dosage forms, primary and secondary packaging for drugs.
“The capacity of the production facilities of the enterprise will make it possible to produce more than 150,000 units per year, which is also facilitated by convenient logistics and cooperation within the cluster of medical technologies of Technopolis Moscow SEZ, of which the company is to become a new resident,” said Gennady Degtev, General Director of the Technopolis Moscow SEZ.
The drug manufacturer specializes in the provision of the Russian healthcare system with modern genetically engineered drugs for the treatment of severe and socially significant pulmonological, cardiovascular, and orphan diseases. The Ministry of Health of the Russian Federation has included them in the list of vital and essential medicines.
As it became known earlier, Technopolis Moscow SEZ is going to launch the production of medicines and medical products.
